Cassava settles SEC charges related to Alzheimer’s candidate for $40M
Cassava Sciences (NASDAQ:SAVA) has agreed to pay $40M to settle claims by the U.S. Securities and Exchange Commission (SEC) that the drug developer made misleading claims about the 2020 trial results of its Alzheimer’s drug candidate,
Alzheimer’s Drug Developer Cassava Paying $40 Million to Settle Doctored Data Claims
The Securities and Exchange Commission alleged that a researcher for the company manipulated trial data to make its drug results look more promising.
Cassava Sciences Shares Lower Premarket on $40M Penalty to Settle Doctored Data Claims
The SEC also said Dr. Hoau-Yan Wang, a Cassava consultant, was charged with manipulating the reported clinical trial results. Without admitting or denying the violations, Wang agreed to cease and desist from future violations and to pay a monetary penalty, the SEC said.
SEC Announces $40 Mln Settlement With Cassava Sciences Over Misleading Alzheimer's Trial Statements
The U.S. Securities and Exchange Commission announced Cassava Sciences Inc. (SAVA), its founder and former CEO, Remi Barbier, and its
Cassava Sciences shares fall after SEC charges for misleading Alzheimer's drug trial claims
Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission charged the biopharmaceutical company and two former executives for misleading claims about the results of Alzheimer's clinical trials.
Cassava Sciences settles SEC charges of ‘misleading’ Alzheimer’s trial claims
Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S. securities regulators, who had charged the pharma company and two former executives for “misleading claims” about an Alzheimer’s clinical trial.
Cassava Sciences and former execs, facing SEC charges for misleading claims, agree to fines
Cassava and former executives were charged Thursday by the SEC with making misleading claims in 2020 about trials for the Alzheimer's drug simufilam, and agreed to pay fines.
alzheimersnewstoday18h
Simufilam found safe in review of ongoing Alzheimer’s clinical trials
After a third review of safety data, an independent board recommended two trials of simufilam for Alzheimer's continue ...
Cassava's Simufilam: Safe On The Outside, Scrambled On The Inside
Cassava's financial challenges and data integrity concerns remain critical. Learn why SAVA stock is rated a strong sell given ...
Cassava Sciences Resolves SEC Investigation
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company ...
Benzinga.com3d
Cassava Sciences Stock Rises On Interim Safety Review Of Simufilam Phase 3 Trials
An independent DSMB reviewed interim safety data for simufilam and recommended the trials proceed without modifications. Two ongoing trials with over 1,900 Alzheimer’s patients; top-line results ...
Why I'm Avoiding Cassava Stock For Now
Cassava Sciences' stock rose 9% after completing a trial of its Alzheimer's drug, Simufilam, but the company's future remains ...
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials.The DSMB Recommended ...
Cassava Sciences Unusual Options Activity For September 23
Following our analysis of the options activities associated with Cassava Sciences, we pivot to a closer look at the company's ...